Texas A&M Basketball

McMillan saw 40 minutes of 'aggressive play' in 41-point win vs. Manhattan

Following a record-breaking 3-point performance, Bucky McMillan's Aggies are back in action on Tuesday night, facing Mississippi Valley State. The head coach joined Monday's edition on TexAgs Live to preview the week ahead against the Delta Devils and FSU on Friday.
By Billy Liucci
November 24, 2025
2.1k Views
Discuss
Story Poster
Photo by Will Huffman, TexAgs

Key notes from Bucky McMillan interview

  • I know people are results-oriented with scores. That win against Montana, based on what they did, they had some wild shots. That was a great win. People will say they cut the lead to five. It is a great win when the team hits the number of threes that they did. They are picked to win their league. They’ve won those kinds of games. We watched our lead evaporate in the game against UCF. These guys are coming together.
To view this content, you must be a TexAgs Premium subscriber.
Get Premium for $1
See Subscription Benefits →
Trial only available to users who have never subscribed or participated in a previous trial
Discuss
Tags
Billy Kennedy Bucky McMillan Olin Buchanan TexAgs Live David Nuño Luke Evangelist TexAgs Live Feature Texas A&M vs. Manhattan College Texas A&M vs. Mississippi Valley State Texas A&M vs. Florida State Rubén Dominguez Mackenzie Mgbako
Show All
Basketball Texas A&M Florida State Mississippi Valley State Manhattan College 2025-2026
More Basketball
See All →
TexAgs Rewind (11/24)
By TexAgs Live
5 Thoughts: Texas A&M 109, Manhattan 68
By Luke Evangelist
Photo Gallery: Aggies rain 3-pointers on Jaspers in 109-68 beatdown
By Cooper Daniels
Game Highlights: Texas A&M 109, Manhattan 68
By Cade Bickham
Discussion from...

McMillan saw 40 minutes of 'aggressive play' in 41-point win vs. Manhattan

782 Views | 0 Replies | Last: 6 hrs ago by Liucci
There are not any replies to this post yet.
Refresh
Page 1 of 1
 
×
subscribe Verify your student status
See Subscription Benefits
Trial only available to users who have never subscribed or participated in a previous trial.